Inflammation, immune activation, immunological and virological evolution following the end of 4^th STI (week 0) until week 48 of follow-up.

Values are median and IQR *p<0.05 ART: Antiretroviral treatment STI: structured treatment interruptions srIL-2: seric receptor for IL-2 SFC: Spot Forming Cells PBMC: Peripheral blood mononuclear cells Inflammation, immune activation, immunological and virological evolution following the end of 4th STI (week 0) until week 48 of follow-up.